Compare CMPR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | AAPG |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | Ireland | China |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2005 | 2024 |
| Metric | CMPR | AAPG |
|---|---|---|
| Price | $88.86 | $17.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $86.50 | $48.40 |
| AVG Volume (30 Days) | ★ 193.1K | 4.3K |
| Earning Date | 04-29-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 553.45 | N/A |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $3,736,643,000.00 | N/A |
| Revenue This Year | $10.43 | $290.34 |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $23.78 | ★ N/A |
| Revenue Growth | ★ 9.80 | N/A |
| 52 Week Low | $56.34 | $16.36 |
| 52 Week High | $106.58 | $48.45 |
| Indicator | CMPR | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 41.01 |
| Support Level | $88.26 | $16.62 |
| Resistance Level | $105.61 | $18.17 |
| Average True Range (ATR) | 4.14 | 0.54 |
| MACD | -1.08 | -0.03 |
| Stochastic Oscillator | 9.56 | 28.63 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.